Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
No takes yet. Share an insight, caveat, or question.
Olesinski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: